Polaris Capital Management’s Cytokinetics CYTK Stock Holding History

Polaris Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.7M	Buy	+266,900	New	+$19.2M	2.14%	14

Other funds holding CYTK

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Polaris Capital Management's CYTK Position: Q2 2026 in Review

Polaris Capital Management opened a new position in Cytokinetics (CYTK) in Q2 2026: 266,900 shares worth $22.7M. The stake represents 2.14% of the portfolio and ranks #14 among its holdings.

90 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Polaris Capital Management held 266,900 shares of Cytokinetics worth $22.7M as of Q2 2026.
Cytokinetics was a new Polaris Capital Management position in Q2 2026.
Cytokinetics made up 2.14% of Polaris Capital Management's portfolio in Q2 2026, its #14 holding.
90 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Polaris Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.